Key result
Insulin treatment resulted in less severe ischemic myocardial dysfunction during dipyridamole infusion compared to glibenclamide (peak stress LVEF 45% vs 37%, P<0.001).
Why the study?
Does insulin therapy improve ischemia-induced myocardial dysfunction compared to glibenclamide in patients with type 2 diabetes and coronary artery disease?
Population
19 consecutive patients with type 2 diabetes and coronary artery disease
Comparison
Insulin therapy for 12 weeks vs Glibenclamide therapy for 12 weeks
Design
RCT, randomly assigned
Follow-up
12 weeks per treatment arm
Authors
Loading...
Supports insulin preference over glibenclamide to lessen ischemia-induced LV dysfunction in T2DM-CAD; extends RCT evidence on antidiabetic myocardial effects.
RCT (n=19)
Crossover
Does insulin therapy improve ischemia-induced myocardial dysfunction compared to glibenclamide in patients with type 2 diabetes and coronary artery disease?
Absolute Event Rate: 45% vs 37%
p-value: p=<0.001
In patients with type 2 diabetes and coronary artery disease, insulin therapy is associated with less severe ischemia-induced myocardial dysfunction during dipyridamole stress compared to glibenclamide.
Scognamiglio et al. (2002) conducted an RCT in Type 2 diabetes and coronary artery disease (n=19). Insulin vs. Glibenclamide was evaluated on Peak stress left ventricular ejection fraction (LVEF) during dipyridamole infusion (p=<0.001). Insulin treatment resulted in less severe ischemic myocardial dysfunction during dipyridamole infusion compared to glibenclamide (peak stress LVEF 45% vs 37%, P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: